Yorkshire Lung Screening Trial (YLST)

Lung cancer is the biggest cancer killer in Yorkshire, with most patients presenting with advanced, incurable disease. Checking people at high risk of lung cancer with regular scans (screening) detects early, curable cancer and reduces deaths by one fifth. Lung cancer screening is not currently available in the UK, and it is not clear exactly which people would most benefit.

Screening high-risk patients with low-dose computed tomography (LDCT) reduced lung cancer mortality by 20% in a large US trial. Unresolved issues for UK implementation include clarification of which high-risk group should be invited for screening to maximise efficacy and cost-effectiveness, and how to improve participation by reducing barriers to screening. The Yorkshire Lung Screening Trial will evaluate a community-based screening programme in mobile units across Leeds through a Zelen's design study, allowing assessment of the overall effect of screening across the population. Three proposed strategies to identify high risk patients for screening will be prospectively compared for the first time.

Privacy Notice: How we use your research data

Funding
Members

Funding

Funder(s):

Yorkshire Cancer Research

Members

Internal Staff

External Collaborators

Dr Matthew Callister, Leeds Teaching Hospitals
Dr Michael Darby, Leeds Teaching Hospitals
Dr Phil Crosbie, University Hospital of South Manchester
Dr Richard Booton, University Hospital of South Manchester
Professor David Baldwin, University of Nottingham
Professor Sam Janes, University College London
Dr Samantha Quaife, University College London
Professor Una MacLeod, Hull York Medical School
Dr Michael Messenger, NIHR Diagnostic Evidence Co-operative
Professor Henrik Moller, King College London
Professor Richard Neal, University of Leeds